COMPARATIVE EFFICACY AND SAFETY OF ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE VERSUS DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA USING A MATCHING-ADJUSTED INDIRECT COMPARISON

被引：0
|
作者：
Leleu, X. [1 ]
Delea, T. [2 ]
Guyot, P. [3 ]
Moynahan, A. [2 ]
Singh, E. [4 ]
Tekle, C. [4 ]
Lin, P. [4 ]
机构：
[1] Univ Poitiers Hosp, Poitiers, France
[2] Policy Anal Inc, Brookline, MA USA
[3] Sanofi, Paris, France
[4] Sanofi, Cambridge, MA USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC34
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [41] Health-Related Quality of Life With Pomalidomide plus Dexamethasone plus Daratumumab After Lenalidomide in Relapsed or Refractory Multiple Myeloma Patients
    Reece, Donna
    Bahlis, Nizar J.
    Samaras, Christy Joy
    Sebag, Michael
    Berdeja, Jesus
    Ganguly, Siddhartha
    Matous, Jeffrey
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Agarwal, Amit
    Chung, Weiyuan
    Zafar, Faiza
    Siegel, David S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E277 - E278
  • [42] A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mikhael, J.
    Richardson, P.
    Usmani, S.
    Raje, N.
    Bensinger, W.
    Kanagavel, D.
    Gao, L.
    Ziti-ljajic, S.
    Anderson, K.
    HAEMATOLOGICA, 2017, 102 : 168 - 168
  • [43] Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience
    Moustafa, Muhamad Alhaj
    Parrondo, Ricardo
    Abdulazeez, Mays F.
    Roy, Vivek
    Sher, Taimur
    Alegria, Victoria R.
    Warsame, Rahma M.
    Larsen, Jeremy
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Kapoor, Prashant
    Fonseca, Rafael
    Buadi, Francis K.
    Dingli, David
    Hayman, Suzanne R.
    Reeder, Craig B.
    Agrawal, Arshi
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    BLOOD, 2020, 136
  • [44] Daratumumab, Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naive Relapsed Refractory Multiple Myeloma Patients
    Ouchveridze, Evguenia
    Singh, Chandandeep
    Atrash, Shebli
    Paul, Barry
    Mohan, Meera
    Alkharabsheh, Omar
    Afrough, Aimaz
    Cui, Wei
    Mahmoudjafari, Zahra
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2022, 140 : 7164 - 7165
  • [45] Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis
    Sunami, Kazutaka
    Ikeda, Takashi
    Huang, Shang-Yi
    Wang, Ming-Chung
    Koh, Youngil
    Min, Chang Ki
    Yeh, Su-Peng
    Matsumoto, Morio
    Uchiyama, Michihiro
    Iyama, Satoshi
    Shimazaki, Chihiro
    Lee, Jae Hoon
    Kim, Kihyun
    Kaneko, Hitomi
    Kim, Jin Seok
    Lin, Tung-Liang
    Campana, Frank
    Tada, Keisuke
    Iida, Shinsuke
    Suzuki, Kenshi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : E751 - E761
  • [46] Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
    Jianming He
    Heather Berringer
    Bart Heeg
    Haoyao Ruan
    Tobias Kampfenkel
    Harikumaran R. Dwarakanathan
    Stephen Johnston
    João Mendes
    Annette Lam
    Sacheeta Bathija
    Emma K. Mackay
    Advances in Therapy, 2022, 39 : 4230 - 4249
  • [47] Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma
    He, Jianming
    Berringer, Heather
    Heeg, Bart
    Ruan, Haoyao
    Kampfenkel, Tobias
    Dwarakanathan, Harikumaran R.
    Johnston, Stephen
    Mendes, Joao
    Lam, Annette
    Bathija, Sacheeta
    Mackay, Eric
    ADVANCES IN THERAPY, 2022, 39 (09) : 4230 - 4249
  • [48] OPTIMIZATION OF POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED MYELOMA MULTIPLE PATIENTS
    De Miguel, D.
    Gil, A.
    Golbano, N.
    Diaz, M.
    Guillen, H.
    Vazquez, A.
    Pinedo, B.
    HAEMATOLOGICA, 2017, 102 : 790 - 791
  • [49] Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3trial
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria -Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Kampfenkel, Tobias
    Liu, Weiping
    Wang, Jianping
    Kosh, Michele
    Tran, Namphuong
    Carson, Robin
    Sonneveld, Pieter
    LANCET HAEMATOLOGY, 2023, 10 (10): : E813 - E824
  • [50] Isatuximab, pomalidomide and dexamethasone versus pomalidomide and dexamethasone in multiple myeloma in third line of treatment or more: what results after prolonged follow-up?
    Nass, Loick
    Ianotto, Jean-Christophe
    HEMATOLOGIE, 2022, 28 (02): : 109 - 110
12345